相关实验视频

Updated: Jun 1, 2025

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

在临床实践中,ofatumumab的实际有效性,持久性,耐受性和安全性

Moein Amin¹, Tucker Harvey², Dan Michael Pineda³

¹Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, OH, USA.

Neurodegenerative disease management

|January 21, 2025

概括

在复发性多发性硬化症 (MS) 患者中,Ofatumumab (OMB) 在12个月内显示出高效率和持续性. 这项现实世界的研究证实了OMB的OMB.

科学领域:

神经学神经学
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

复发性多发性硬化症 (MS) 是一种慢性自身免疫性疾病,影响中枢神经系统.
疾病修饰疗法 (DMT) 对于管理多发性硬化症的进展和症状至关重要.
奥法图马布 (OMB) 是一种有效的B细胞耗尽的DMT,用于复发性MS.

研究的目的:

为了评估ofatumumab (OMB) 在多种复发性多发性硬化症 (MS) 患者群体中的12个月的实际有效性,持久性,耐受性和安全性.
评估开始OMB治疗的MS患者的临床,患者报告和放射性结果.
提供关于OMB在常规临床实践中的实际应用和患者结果的见解.

主要方法:

从2020年10月至2022年8月期间在两个多发性硬化中心开始OMB的175名患者的电子病历的回顾性审查.
对人口统计,疾病特征和6个月和12个月后续数据的分析.
包括临床复发率,患者报告的结果和放射性发现.

主要成果:

在175名患者中,9.7%的患者在12个月内停止了OMB治疗,主要是由于耐受性.
观察到复发的显著减少,在研究队伍中,在开始12个月后仅发生一次复发.
该队列包括74%的女性,80%的复发性复发性MS或临床隔离综合征,之前有87%的DMT暴露.

结论:

在12个月后,Ofatumumab (OMB) 在现实世界复发性多发性硬化症 (MS) 患者群体中表现出高效,强大的持久性和有利的安全性和耐受性概况.
这些发现支持使用OMB作为MS管理的有价值的治疗选择.
需要进一步的长期研究来充分阐明OMB的持续益处和安全性.

关键词:

这就是Ofatumumabumab.改变疾病的疗法.有效性有效性有效性.多发性硬化症多发性硬化症现实世界的真实世界.可以容忍的耐受性.

更多相关视频

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

相关概念视频

Bioequivalence: Overview

Bioequivalence: Overview

Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...